Clinical Trial Update: Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing cetuximab plus cisplatin in patients with metastatic or recurrent head and neck cancer that has not responded to cisplatin chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED